NEWS
Future PharmaTech Secures Funding, Targets Q1 2026 for Clinical Trial Authorization
Successfully completed new funding round with strategic investor support, demonstrating market confidence. Funds will advance preclinical research and trial preparation, targeting FDA IND authorization in Q1 2026.
Notice of Conversion to Dematerialized Shares
Starting August 28, 2025, all outstanding ordinary shares will be converted to dematerialized shares, recorded under shareholders' names in TDCC accounts. Details will be provided by our shareholder services agent.
Future PharmaTech 2025 Annual Shareholders Meeting Successfully Concluded
Thank you to all shareholders for your participation and support. Your valuable feedback drives our progress. We remain committed to innovation and creating greater value for shareholders.
D&B Enterprise Certification Cloud Badge Delivered
Future PharmaTech obtained D&B enterprise certification with D-U-N-S®Registered™ badge, enhancing corporate credibility and international recognition. This global standard facilitates stronger business partnerships.
Future PharmaTech Signs ED Drug Licensing Deal with PBF Group
PBF Group signed ED drug licensing agreement with Future PharmaTech, securing Taiwan patent rights and priority negotiation for Greater China. The 505(b)(2) pathway accelerates entry into men's health market.
Future PharmaTech's Two Lead Drug Candidates Set to Enter Phase II Trials
Targeting vascular dementia and sexual dysfunction, two compounds entering Phase II clinical trials next year with strong global market potential. Both programs demonstrate robust competitive positioning.
Prof. Chao Ming-Wei Leads R&D Strategy – Dementia Drug Poised for Clinical Entry
Toxicology expert Prof. Chao Ming-Wei advises Future PharmaTech on dementia treatment development. Related drugs expected to begin clinical trials next year, bringing new hope to Alzheimer's patients.
